FibroGen to Present at Goldman Sachs 45th Annual Healthcare Conference

SAN FRANCISCO, June 3, 2024 — FibroGen, Inc. (NASDAQ: FGEN) has revealed that CEO Thane Wettig will be involved in a Fireside Chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled to take place in Miami, Florida on Monday, June 10, 2024, between 10:00 and 10:35 AM Eastern Time. During the conference, company management will also engage in one-on-one meetings with potential investors.

For those interested in the event, a live audio webcast will be accessible via the "Events & Presentations" section of the FibroGen Investor webpage. Additionally, a replay of the webcast will be available for a duration of 90 days post-event.

About FibroGen

FibroGen, Inc., is a biopharmaceutical firm dedicated to the rapid development of innovative therapies, primarily focusing on the complexities of cancer biology. The company is currently advancing several key clinical programs:

1. Pamrevlumab: This fully human anti-CTGF monoclonal antibody is being tested for its effectiveness in treating metastatic pancreatic cancer as well as locally advanced unresectable pancreatic cancer (LAPC).

2. Roxadustat: Known under the brand names 爱瑞卓® and EVRENZOTM, this drug has received approval in China, Europe, Japan, and several other countries for managing anemia in chronic kidney disease (CKD) patients both on and off dialysis. Roxadustat is also undergoing clinical trials for treating chemotherapy-induced anemia (CIA), and a Supplemental New Drug Application (sNDA) for this indication has been accepted for review by the China Health Authority.

3. FG-3246 (FOR46): This first-in-class antibody-drug conjugate (ADC) that targets CD46 is under development for treating metastatic castration-resistant prostate cancer. The development plan includes creating a related CD46-targeted PET biomarker.

Additionally, FibroGen is broadening its research and development scope by incorporating two immuno-oncology product candidates aimed at treating solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!